While IDH‐mutant non‐co‐deleted group showed an intermediate value of TMB between IDH‐wildtype and the IDH‐co‐deleted mutant; no statistically significant difference was observed between TMB values of the two IDH‐mutant subtypes; namely, IDH‐mutant glioma with 1p/19q codeletion and IDH‐mutant glioma without 1p/19q codeletion [56] (current WHO nomenclatures are oligodendroglioma IDH‐mutant and 1p/19q‐codeleted, and astrocytoma IDH‐mutant, respectively). This evidence concerns the gene IDH1 and central nervous system cancer.